Advertisement ViroMed launches joint study with Biologics Delivery Systems - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

ViroMed launches joint study with Biologics Delivery Systems

ViroMed has launched a joint study with Biologics Delivery Systems Group of Cordis, a Johnson & Johnson company.

The study will evaluate the efficacy of VM202 for the treatment of coronary artery disease, using Biologics Delivery Systems Group’s Noga Cardiac Navigation System and the Myostar injection Catheter.

Successful completion of this study will facilitate the initiation of the US Phase I study, in which VM202, an angiogenic therapeutic product of ViroMed, will be delivered with the Noga injection system to patient with heart disease without the need for surgical intervention. Approval for this clinical trial in the US is expected during fourth quarter of 2008. Independently, the Phase I clinical trial for VM202 for the treatment of peripheral artery disease is ongoing at Minneapolis Heart Institute in the US.

Sunyoung Kim, CEO of ViroMed, said: “We hope and anticipate that this initial collaboration will lead to a fruitful and productive partnership between the two companies and will allow us to become a global player in the cardiovascular therapeutic market.”